Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von DropStone 

Eli Lilly Corp. diskutieren

Eli Lilly Corp.

WKN: 858560 / Symbol: LLY / Name: Eli Lilly / Aktie / Pharmazeutika / Large Cap /

829,00 €
0,46 %

Einschätzung Buy
Rendite (%) 53,73 %
Kursziel 597,05
Veränderung
Endet am 09.10.24

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 47,34 %
Kursziel 633,29
Veränderung
Endet am 11.10.24

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Morgan Stanley from $640.00 to $673.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 49,45 %
Kursziel 670,67
Veränderung
Endet am 20.10.24

Eli Lilly and Company (NYSE: LLY) had its "buy" rating re-affirmed by analysts at UBS Group AG. They now have a $710.00 price target on the stock, up previously from $612.00.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 51,35 %
Kursziel 592,58
Veränderung
Endet am 23.10.24

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 51,63 %
Kursziel 633,69
Veränderung
Endet am 23.10.24

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Citigroup Inc. from $525.00 to $675.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 56,18 %
Kursziel 673,48
Veränderung
Endet am 03.11.24

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Morgan Stanley from $673.00 to $722.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 51,16 %
Kursziel 580,86
Veränderung
Endet am 15.11.24

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 53,82 %
Kursziel 591,57
Veränderung
Endet am 29.11.24

Eli Lilly and Company (NYSE: LLY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $650.00 price target on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 56,87 %
Kursziel 748,76
Veränderung
Endet am 19.12.24

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Morgan Stanley from $727.00 to $822.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 43,21 %
Kursziel 625,12
Veränderung
Endet am 23.01.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Barclays PLC from $630.00 to $680.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 42,96 %
Kursziel 581,49
Veränderung
Endet am 23.01.25

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 42,35 %
Kursziel 641,90
Veränderung
Endet am 24.01.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Wells Fargo & Company from $650.00 to $700.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 37,86 %
Kursziel 579,60
Veränderung
Endet am 01.02.25

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $630.00 price target on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 26,63 %
Kursziel 766,92
Veränderung
Endet am 06.02.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Wells Fargo & Company from $700.00 to $825.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 24,82 %
Kursziel 802,46
Veränderung
Endet am 07.02.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at BMO Capital Markets from $710.00 to $865.00. They now have an "outperform" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 22,97 %
Kursziel 751,76
Veränderung
Endet am 07.02.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Barclays PLC from $680.00 to $810.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 22,97 %
Kursziel 747,12
Veränderung
Endet am 07.02.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Morgan Stanley from $763.00 to $805.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat

Einschätzung Buy
Rendite (%) 22,52 %
Kursziel 788,80
Veränderung
Endet am 07.02.25

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Truist Financial Co. from $650.00 to $850.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat